Clinical Trial Update: Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-) [Phase 2]

View source ↗

Summary

Clinical trial update evaluating erlotinib as second- or third-line therapy in non-small cell lung cancer patients with EGFR mutation-negative and MET-negative …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Li Zhang | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN